Literature DB >> 24763641

Benchmarking and validation of a Geant4-SHADOW Monte Carlo simulation for dose calculations in microbeam radiation therapy.

Iwan Cornelius1, Susanna Guatelli1, Pauline Fournier1, Jeffrey C Crosbie2, Manuel Sanchez Del Rio3, Elke Bräuer-Krisch3, Anatoly Rosenfeld1, Michael Lerch1.   

Abstract

Microbeam radiation therapy (MRT) is a synchrotron-based radiotherapy modality that uses high-intensity beams of spatially fractionated radiation to treat tumours. The rapid evolution of MRT towards clinical trials demands accurate treatment planning systems (TPS), as well as independent tools for the verification of TPS calculated dose distributions in order to ensure patient safety and treatment efficacy. Monte Carlo computer simulation represents the most accurate method of dose calculation in patient geometries and is best suited for the purpose of TPS verification. A Monte Carlo model of the ID17 biomedical beamline at the European Synchrotron Radiation Facility has been developed, including recent modifications, using the Geant4 Monte Carlo toolkit interfaced with the SHADOW X-ray optics and ray-tracing libraries. The code was benchmarked by simulating dose profiles in water-equivalent phantoms subject to irradiation by broad-beam (without spatial fractionation) and microbeam (with spatial fractionation) fields, and comparing against those calculated with a previous model of the beamline developed using the PENELOPE code. Validation against additional experimental dose profiles in water-equivalent phantoms subject to broad-beam irradiation was also performed. Good agreement between codes was observed, with the exception of out-of-field doses and toward the field edge for larger field sizes. Microbeam results showed good agreement between both codes and experimental results within uncertainties. Results of the experimental validation showed agreement for different beamline configurations. The asymmetry in the out-of-field dose profiles due to polarization effects was also investigated, yielding important information for the treatment planning process in MRT. This work represents an important step in the development of a Monte Carlo-based independent verification tool for treatment planning in MRT.

Entities:  

Keywords:  Monte Carlo; dosimetry; microbeam radiation therapy

Year:  2014        PMID: 24763641     DOI: 10.1107/S1600577514004640

Source DB:  PubMed          Journal:  J Synchrotron Radiat        ISSN: 0909-0495            Impact factor:   2.616


  5 in total

1.  Non-conventional Ultra-High Dose Rate (FLASH) Microbeam Radiotherapy Provides Superior Normal Tissue Sparing in Rat Lung Compared to Non-conventional Ultra-High Dose Rate (FLASH) Radiotherapy.

Authors:  Michael D Wright; Pantaleo Romanelli; Alberto Bravin; Geraldine Le Duc; Elke Brauer-Krisch; Herwig Requardt; Stefan Bartzsch; Ruslan Hlushchuk; Jean-Albert Laissue; Valentin Djonov
Journal:  Cureus       Date:  2021-11-06

Review 2.  Microbeam radiation therapy - grid therapy and beyond: a clinical perspective.

Authors:  Elisabeth Schültke; Jacques Balosso; Thomas Breslin; Guido Cavaletti; Valentin Djonov; Francois Esteve; Michael Grotzer; Guido Hildebrandt; Alexander Valdman; Jean Laissue
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

3.  Hybrid dose calculation: a dose calculation algorithm for microbeam radiation therapy.

Authors:  Mattia Donzelli; Elke Bräuer-Krisch; Uwe Oelfke; Jan J Wilkens; Stefan Bartzsch
Journal:  Phys Med Biol       Date:  2018-02-13       Impact factor: 3.609

4.  Perspectives for microbeam irradiation at the SYRMEP beamline.

Authors:  Elisabeth Schültke; Stefan Fiedler; Ralf Hendrik Menk; Felix Jaekel; Diego Dreossi; Katia Casarin; Giuliana Tromba; Stefan Bartzsch; Stephan Kriesen; Guido Hildebrandt; Fulvia Arfelli
Journal:  J Synchrotron Radiat       Date:  2021-02-15       Impact factor: 2.616

5.  A high-resolution dose calculation engine for X-ray microbeams radiation therapy.

Authors:  Sarvenaz Keshmiri; Sylvan Brocard; Raphaël Serduc; Jean-François Adam
Journal:  Med Phys       Date:  2022-04-12       Impact factor: 4.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.